Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, USA.
University of Arizona Cancer Center, Tucson, AZ, USA.
Oncogene. 2020 Mar;39(12):2597-2611. doi: 10.1038/s41388-020-1168-9. Epub 2020 Jan 28.
Resistance to chemotherapy represents a major obstacle to the successful treatment of non-small-cell lung cancer (NSCLC). The goal of this study was to determine how PIM kinases impact mitochondrial dynamics, ROS production, and response to chemotherapy in lung cancer. Live-cell imaging and microscopy were used to determine the effect of PIM loss or inhibition on mitochondrial phenotype and ROS. Inhibition of PIM kinases caused excessive mitochondrial fission and significant upregulation of mitochondrial superoxide, increasing intracellular ROS. Mechanistically, we define a signaling axis linking PIM1 to Drp1 and mitochondrial fission in lung cancer. PIM inhibition significantly increased the protein levels and mitochondrial localization of Drp1, causing marked fragmentation of mitochondria. An inverse correlation between PIM1 and Drp1 was confirmed in NSCLC patient samples. Inhibition of PIM sensitized NSCLC cells to chemotherapy and produced a synergistic antitumor response in vitro and in vivo. Immunohistochemistry and transmission electron microscopy verified that PIM inhibitors promote mitochondrial fission and apoptosis in vivo. These data improve our knowledge about how PIM1 regulates mitochondria and provide justification for combining PIM inhibition with chemotherapy in NSCLC.
化疗耐药是影响非小细胞肺癌(NSCLC)成功治疗的主要障碍。本研究旨在确定 PIM 激酶如何影响肺癌中线粒体动力学、ROS 产生和对化疗的反应。通过活细胞成像和显微镜观察来确定 PIM 缺失或抑制对线粒体表型和 ROS 的影响。抑制 PIM 激酶会导致过度的线粒体分裂和线粒体超氧化物的显著上调,从而增加细胞内 ROS。从机制上讲,我们定义了一条信号通路,将 PIM1 与肺癌中的 Drp1 和线粒体分裂联系起来。PIM 抑制显著增加了 Drp1 的蛋白水平和线粒体定位,导致线粒体明显碎片化。在 NSCLC 患者样本中证实了 PIM1 和 Drp1 之间呈负相关。抑制 PIM 可使 NSCLC 细胞对化疗敏感,并在体外和体内产生协同的抗肿瘤反应。免疫组织化学和透射电子显微镜验证了 PIM 抑制剂在体内促进线粒体分裂和细胞凋亡。这些数据提高了我们对 PIM1 如何调节线粒体的认识,并为将 PIM 抑制与 NSCLC 中的化疗相结合提供了依据。